InflaRx Outlined Multiple Data Analyses Of The Phase 3 Study For Vilobelimab In Pyoderma Gangrenosum, Which Was Terminated Earlier In 2025 After An Independent Data Monitoring Committee Recommended To Stop The Trial Early Due To Futility

Benzinga · 12/30/2025 12:32
  • While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to futility regarding its prespecified primary endpoint (as previously disclosed), subsequent post-hoc analyses suggest a positive trend in favor of vilobelimab, with signals indicating a potentially consistent treatment effect
  • InflaRx anticipates meeting with the FDA to determine a potential development path forward in PG, which the Company anticipates would only be conducted in collaboration with a partner